Lab expects to grow 20% producing generic

Campinas-Today being celebrated the national day of generic drugs and this year also marks 17 years since the first generic medicines have been registered in the country and its production has been released. The Germed Pharma, 100% brazilian multinational of the CN Group Pharma, which also holds the marks of the EMS Labs, Legrand and new chemistry, produces 7 million units of medicines/month, based in Campinas and plant, in Hortolândia. The holding company has factories in Hortolândia and in Manaus. She became an independent company in 2009. Was previously a product line of EMS. In the first year of existence in 2009 made 192 million price/R$ factory and in 2015 closed with a turnover of 1.28 billion R$ and occupies the 14th position in the ranking of the leading laboratories in the country, with more than 10 years of existence. Currently the company is part of a process of internationalization and acts in some important areas, such as the hospital in Portugal and also in Spain. The ceo of Germed, Cosme dos Santos, said the pharmaceutical laboratories in Brazil are operating with smaller margins. The prices of medicines are regulated by the federal Government, which determines what will be always the percentage of increase. "It is the Government that says what will be increased and we have suffered in recent years. The Government always gave the increase below inflation or sometimes even near the inflation. But the dollar has always been above. This year the Government released inflation and the rate of increase was in 12.5%, but the dollar in the last 4 months increased above 10%. Pay the raw materials in dollars and the banks are being strangled, "said Cosme dos Santos. The Germed was the only one to produce in the southern hemisphere the Sigmasporin, used against the rejection of transplanted organs. "I visited this medication in Brazil on hospital row," he recalls. Within the strategic planning for the next release is Germed 60 days of generic Tadalafil, which is the Cialis, used in the treatment of erectile dysfunction, which moves R$ 345 million/year. "Last year it was awful and we had almost zero growth. For 2016, we intend to grow in the generic sector 20% from 2015. The price/factory, we expect to close with a turnover of 2016 R$ 1.6 billion, "he says. According to the World Health Organization (who), the brazilian population will jump from 12.5% to 30% of seniors until 2050. Given the fact the Germed Pharma has returned its attention to this population that live longer. "From these data we''ve been getting ready for the future with differentiated actions like, for example, more than 1,200 events '' Germed in action '' by our team of relationship Marketing, responsible for ensuring the presence of our products in pharmacies across the country," he points out. According to him, the events '' in action '' Germed comprise provision of services such as gauging of pressure and glycemia, informative about health and well-being, especially for the elderly. The actions are carried out in partnership with drugstores and pharmacies and annually the Germed Pharma meets more than 60 1000 people. Still about their strategies, Germed Pharma, accompanying the growth of generics until May this year has offered more than 10 new products. Reinforcing the issue of accessibility, Generic Germed aims, through the end of 2016, overcome the 15 releases of new molecules and/or presentations. "The strategy of accessibility of medicine through the continuous expansion of Germed in Brazilian cities and also part of our DNA, as well as the quality and affordability of our products. We have a strong presence, through our generics, in more than 50 1000 pharmacies and drugstores in all Brazilian States, "explains. With the same active ingredient, dosage and formula, administered the same way and with the same dosage and indication of the medicines, generic reference still face the resistance of the population since its launch. But the scenario is changing.